Company intelligence / Profile preview

Curatis

Ownership: Private
Development stage: Other

Overview

Curatis focuses on repurposing existing drugs for rare and specialty care diseases. Its lead clinical program is in Phase 2 for atrial fibrillation. The company leverages compounds with established safety/efficacy data to accelerate development timelines and reduce risk[4][5].

Therapeutic areas: Rare DiseasesNeurologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

KIN001

3 more assets in the full pipeline.

Partnerships

Co-development partnerships with small/medium biotech/pharma companies and contract research/manufacturing organizations; seeking larger pharma partners for late-stage licensing/co-development

Beyond the preview

Go deeper on Curatis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curatis.